24 results
8-K
EX-99.1
APGE
Apogee Therapeutics Inc.
5 Mar 24
Regulation FD Disclosure
8:15am
relative to Q6M APG777 Corporate
APG808
© Apogee Therapeutics, Inc. 52 APG808 targets the same mechanism as DUPIXENT, which has been validated in COPD … on comparable YTE mAbs Every 8 weeks Every 6 weeks APG808 dosing interval based on PK modeling1 42 (1.6x) 59 (2.3x) Average of YTE mAbs for receptor targets
10-K
2023 FY
APGE
Apogee Therapeutics Inc.
5 Mar 24
Annual report
6:15am
expect to nominate a development candidate for APG990 in 2024. In addition, we believe that blocking multiple targets, such as simultaneous … peak sales of $21 billion in 2031 based on consensus estimates. Although our most advanced program APG777 targets the same mechanism of action
DRS
APGE
Apogee Therapeutics Inc.
9 Feb 24
Draft registration statement
12:00am
targets, such as simultaneous inhibition of IL-13 and OX40L in APG222, could allow us to provide benefit to patients with AD and other I&I indications … and the downstream inflammatory cascade. We believe that blocking multiple targets, such as simultaneous inhibition of IL-13 and OX40L, could allow us to provide
10-Q
EX-10.2
njs pkgv3abgmyofwsd
28 Aug 23
Quarterly report
8:00am
10-Q
EX-10.3
v5snf58bdezeytrb04r
28 Aug 23
Quarterly report
8:00am
10-Q
EX-10.4
ykfzviq4e hb43dbb
28 Aug 23
Quarterly report
8:00am
10-Q
zmnhqx0okk
28 Aug 23
Quarterly report
8:00am
8-K
EX-99.1
sd4fq7fhdzywq h2vi
28 Aug 23
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
7:35am
8-K
EX-99.1
fon3ug6t
7 Aug 23
Regulation FD Disclosure
7:35am
424B4
i9s6j2d9efz7dyxqi
17 Jul 23
Prospectus supplement with pricing info
4:08pm
S-1
EX-10.7
lgleh9
22 Jun 23
IPO registration
4:19pm
S-1
EX-10.5
6ct yftqye8of9ld6x9
22 Jun 23
IPO registration
4:19pm
S-1
EX-10.9
vhb3e78tg v1are
22 Jun 23
IPO registration
4:19pm
S-1
EX-10.10
78miuj1
22 Jun 23
IPO registration
4:19pm
S-1
bfon2z k3
22 Jun 23
IPO registration
4:19pm
DRS/A
qqglvkzyw
5 Jun 23
Draft registration statement (amended)
12:00am